Abstract
Since the introduction of the Papanicolaou (Pap) test in 1943, cervical cancer mortality has decreased by more than 70%. Once the number one cancer killer of women, cervical cancer now ranks 13th in cancer deaths for women in the United States (1). In 2005, the American Cancer Society (ACS) estimates 10,370 new cases of invasive cervical cancer and 3710 cervical cancer deaths. Five-year survival rates for women with preinvasive lesions have reached nearly 100%, whereas the 5-year survival rate for cervical cancers detected at an early stage is close to 92% (2)
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society Guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342–362.
American Cancer Society. Cancer Facts and Figures. 2005.
Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235–240.
Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277–284.
Ho GY, Bierman R, Beardsle L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 2003; 102:417–427.
US Preventive Services Task Force. Screening for cervical cancer (accessed August 7, 2005 at http://www.ahrq.gov/clinic/uspstf/uspscerv.htm.).
Wright TC, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120–2129.
Wright TC, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet 2003; 189:295–304.
Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
Harper DM. Are we closer to the prevention of HPV-related diseases? J Fam Pract 2005;54(7 Suppl):s10–s16.
Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–1651.
Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364(9447):1757–1765.
Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L-1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271–278.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Clouse, A.L. (2008). Cervical Cancer Detection and Prevention. In: Clouse, A.L., Sherif, K. (eds) Women’s Health in Clinical Practice. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-469-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-59745-469-8_11
Publisher Name: Humana Press
Print ISBN: 978-1-58829-631-3
Online ISBN: 978-1-59745-469-8
eBook Packages: MedicineMedicine (R0)